No Data
No Data
Sirnaomics Announces Completion of IND-Enabling Studies of Safety and Efficacy for STP125G With NHP Models, Targeting ApoC3 for Treatment of Cardiovascular Diseases
Saint Novo Medicine (02257.HK) completed the IND preparation phase study of a cardiovascular disease drug under its subsidiary.
Sanofi-B (02257.HK) announced that it has completed the IND preparation stage study of the target lipoprotein C3 (ApoC3) siRNA therapeutic drug STP125G based on its proprietary GalAhead mxRNA technology, which is the second candidate drug. The safety and efficacy results of non-human primates (NHP) research strongly support the application for IND to the US FDA to initiate Phase I clinical trials of STP125G for cardiovascular disease indications. The company cannot guarantee the success of STP125G in the market.
Shengnuo Medicine-B (02257. HK) announced the completion of the STP125G IND preparation stage study for the safety and efficacy of targeting APOC3 for the treatment of cardiovascular disease in non-human primate models.
On July 12th, 2024 - Sirnaomics Ltd. ("Company", stock code: 2257.HK, together with its subsidiaries, collectively referred to as "Group" or "Sirnaomics"), a leading biopharmaceutical company focused on exploring and developing RNAi therapies in the industry, announced today that the Group has completed the IND preparation study for siRNA therapeutic drug STP125G targeting Apolipoprotein C3 (ApoC3) based on its proprietary GalAhead mxRNA technology. Non-human primates
Stock market abnormality: Sanofi-Aventis-B (02257) rose more than 25% in the mid-trading session, and the second sequence of STP122G anticoagulant treatment clinical trials has been completed.
According to the Zhītōng Finance APP, Sanofi-B (02257) rose more than 25% during trading and as of press time, rose 17.32%, to HKD 5.08, with a turnover of HKD 40.5272 million. On the news front, Sanofi announced that the successful completion of Phase I of the second sequence of clinical trials of STP122G, a GalNAc RNAi therapy for anticoagulant treatment, and the release of interim data. It is reported that the therapeutic product is a novel anticoagulant therapy targeting eleven factors. Safety data shows that dose-limiting toxicity or severe adverse events did not occur and dose-dependent target silencing was observed.
Sirnaomics Finds No Serious Adverse Events During Phase 1 Study for Coagulation Drug
Sirnaomics announced the completion of the Phase I clinical trial of the GalNAc RNAi therapeutic drug STP122G for anticoagulant therapy and released midterm data.
On July 8, 2024, in Hong Kong, Maryland, USA, Germany City and Suzhou, Sirnaomics Ltd. (the "Company", along with its subsidiaries, collectively referred to as the "Group" or "Sirnaomics"; stock code: 2257), an industry-leading biopharmaceutical company focused on exploring and developing RNAi therapies, announced that the Phase I clinical trial of STP122G for anticoagulant therapy has successfully completed the second sequence and announced midterm data. This therapeutic product is a novel anticoagulant targeting Factor XI. Second sequence
No Data